Alpidem
Alpidem (pronounced al-pi-dem) is a non-benzodiazepine anxiolytic medication that was primarily marketed in France before being withdrawn due to its potential for causing liver damage.
Pronunciation
The term 'Alpidem' is pronounced as 'al-pi-dem'.
Etymology
The term 'Alpidem' is derived from the combination of the words 'alpha' and 'pidem', where 'alpha' refers to the first letter of the Greek alphabet and 'pidem' is a common suffix used in the naming of pharmaceutical drugs.
Pharmacology
Alpidem belongs to the class of drugs known as Imidazopyridines, which are primarily used for their sedative and anxiolytic effects. It acts by binding to the GABA receptors in the brain, thereby enhancing the effects of the neurotransmitter GABA, which is known to have calming effects on the nervous system.
History
Alpidem was developed by the French pharmaceutical company Sanofi in the 1980s. It was initially marketed as a safer alternative to benzodiazepines, which were known to have potential for abuse and dependence. However, post-marketing reports of severe liver damage led to its withdrawal from the market in 1995.
Related Terms
- Anxiolytic: A class of medication used to treat anxiety disorders.
- Imidazopyridines: A class of drugs that includes Alpidem.
- GABA: A neurotransmitter in the brain that has calming effects on the nervous system.
- Sanofi: A French multinational pharmaceutical company that developed Alpidem.
See Also
External links
- Medical encyclopedia article on Alpidem
- Wikipedia's article - Alpidem
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski